GLPwatch
Trulicity for Parkinson's disease
dulaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCTrulicity (dulaglutide) is not FDA-approved for Parkinson's disease, and any use for this condition is off-label or investigational. The listed research includes pre-clinical studies suggesting potential protective effects of dulaglutide in Parkinson's disease models, but these findings have not been confirmed in human trials.
AI summary of the sources below.
| Drug | Trulicity (dulaglutide) |
|---|---|
| Condition | Parkinson's disease |
| Approval status | Investigational / off-label |
| Research papers | 4 |
Trulicity is not FDA-approved for parkinson's disease; the research below reflects investigational or off-label study only.
Research on dulaglutide for parkinson's disease (4)
- Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.
- Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System.
- A novel protective modality against rotenone-induced Parkinson's disease: A pre-clinical study with dulaglutide.
- Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.